10x Genomics Inc [TXG] stock prices are down -9.49% to $10.59 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The TXG shares have gain 7.51% over the last week, with a monthly amount drifted -27.71%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
10x Genomics Inc [NASDAQ: TXG] stock has seen the most recent analyst activity on February 13, 2025, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $12 from $25. Previously, Leerink Partners started tracking the stock with Outperform rating on September 03, 2024, and set its price target to $35. On July 22, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $24 on the stock. JP Morgan downgraded its rating to a Neutral and decreased its price target to $20 on July 18, 2024. Deutsche Bank downgraded its rating to a Hold and reduced its price target to $25 on July 10, 2024. Wolfe Research downgraded its rating to Peer Perform for this stock on June 27, 2024. In a note dated June 25, 2024, Guggenheim downgraded an Neutral rating on this stock.
The stock price of 10x Genomics Inc [TXG] has been fluctuating between $9.27 and $42.85 over the past year. Currently, Wall Street analysts expect the stock to reach $30.2 within the next 12 months. 10x Genomics Inc [NASDAQ: TXG] shares were valued at $10.59 at the most recent close of the market. An investor can expect a potential return of 185.17% based on the average TXG price forecast.
Analyzing the TXG fundamentals
The 10x Genomics Inc [NASDAQ:TXG] reported sales of 610.78M for trailing twelve months, representing a drop of -10.30%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.32%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.25 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.21 points at the first support level, and at 9.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.29, and for the 2nd resistance point, it is at 11.99.
Ratios To Look Out For
It’s worth pointing out that 10x Genomics Inc [NASDAQ:TXG]’s Current Ratio is 4.97. On the other hand, the Quick Ratio is 4.26, and the Cash Ratio is 2.92. Considering the valuation of this stock, the price to sales ratio is 2.12, the price to book ratio is 1.82.
Transactions by insiders
Recent insider trading involved Saxonov Serge, Chief Executive Officer, that happened on Feb 28 ’25 when 7942.0 shares were sold. Director, CEO, Serge Saxonov completed a deal on Feb 28 ’25 to buy 7942.0 shares. Meanwhile, Hindson Benjamin J. sold 4573.0 shares on Feb 24 ’25.
